Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Counterpoint.

Journal of nuclear medicine technology·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Theory, Modalities, and Applications Across the Training Continuum.

Journal of nuclear medicine technology·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Practical-Use SCAFFOLD.

Journal of nuclear medicine technology·2026
Same author

From data-rich to evidence-ready: A narrative review of generative artificial intelligence as a statistical scaffold in medical radiation sciences research.

Journal of medical imaging and radiation sciences·2026
Same author

Prostate Cancer, Part 2: PSMA and Beyond.

Journal of nuclear medicine technology·2026
Same author

Enabling research collaboration in medical radiation sciences: A multi-domain perspective.

Journal of medical imaging and radiation sciences·2026

Related Experiment Video

Updated: Apr 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K

Prostate Cancer, Part 1: Contemporary Radioligands.

Geoffrey M Currie1, Eric M Rohren2,3

  • 1School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia; and gcurrie@csu.edu.au.

Journal of Nuclear Medicine Technology
|April 13, 2026
PubMed
Summary

Nuclear medicine offers advanced prostate cancer imaging and therapy beyond PSMA. Understanding non-PSMA radiopharmaceuticals is crucial for personalized treatment selection and developing new theranostic strategies.

Keywords:
imagingnuclear medicineprostate cancerradioligandradionuclide therapytheranostics

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Science

Background:

  • Prostate cancer management requires accurate detection, staging, and treatment selection.
  • Nuclear medicine provides molecular insights into tumor biology, aiding diagnosis and therapy.
  • Non-prostate-specific membrane antigen (PSMA) radiopharmaceuticals are vital for understanding prostate cancer phenotypes.

Purpose of the Study:

  • To provide a biologically structured overview of non-PSMA radiopharmaceuticals in prostate cancer.
  • To explore molecular mechanisms determining radioligand suitability for diagnosis and therapy.
  • To highlight the importance of matching radioligands to tumor biology and clinical goals.

Main Methods:

  • Review of major biologic imaging pathways in prostate cancer (e.g., metabolism, hypoxia, AR signaling).
  • Analysis of radioligand performance determinants (e.g., radionuclide properties, biodistribution).
  • Discussion of strengths, limitations, and clinical implications of non-PSMA tracers.

Main Results:

  • Non-PSMA radioligands target diverse pathways like metabolism, hypoxia, and AR signaling.
  • Radioligand performance depends on physical, chemical, and biological factors.
  • Tumor heterogeneity necessitates a broad molecular imaging approach beyond PSMA.

Conclusions:

  • Non-PSMA radiopharmaceuticals offer complementary roles in specific clinical scenarios and research.
  • Understanding these agents is foundational for advancing prostate cancer theranostics.
  • A broader molecular imaging perspective is essential for managing complex prostate cancer phenotypes.